Anthony King

I am a freelance science journalist based in Dublin, Ireland. I cover a variety of topics in chemical and biological sciences, as well as science policy, health and innovation.

My articles have appeared in Nature, Science, Cell, Chemistry World, New Scientist, the Irish Times, New York Times, EMBO Reports, Chemistry & Industry and more.

I enjoy writing on a wide breadth of subjects, from antibiotics to petrochemicals, bumblebees to asteroid composition, palaeontology to brain development. Previously I worked for a publishing company as a science editor.

My primary degree in science is from Trinity College Dublin and I hold a Master’s degree in science communications from Dublin City University.

Follow @https://twitter.com/AntonyJKing

Business
Why manufacturing Covid vaccines at scale is hard
2021-03-23T09:40:00
Exploring the pinch points vaccine makers face as they ramp up production
News
Green light for world’s first Sars-CoV-2 studies that will infect healthy volunteers
2021-02-24T09:30:00
UK trials will assess how well Covid-19 treatments work and if vaccines protect against new virus variants
Business
Coronavirus variants stymie success of monoclonal antibodies
2021-02-23T15:50:00
Lab-made antibodies can treat and protect people from Covid-19 but are more likely to succeed when administered as a cocktail
News
European commission to reconsider how it announces winners of Marie Curie fellowships
2021-02-17T15:23:00
Some researchers applying for the EU scheme were left in limbo over whether or not they had won an award
Business
Covid vaccination efforts bolstered by trial results from J&J and Novavax
2021-02-04T14:10:00
A miserable January ended with positive news on the vaccine front but new variants added complications
News
Old drugs prove their worth against Covid-19 as search continues for life-saving therapies
2021-01-19T14:55:00
Thousands of patients have now taken part in trials around the world that have helped sift hope from hype
Business
Vaccine approvals offer hope as global Covid cases surge
2021-01-14T16:35:00
A handful of vaccines are now approved and the first doses are being given to patients, with trials for many more candidates nearing completion
Business
Pfizer–BioNTech vaccine gains emergency approvals in US, Canada and beyond
2020-12-14T10:24:00
UK begins vaccinating vulnerable populations after early authorisation
Research
Moths draped in stealth acoustic cloak evade bat sonar
2020-11-26T09:30:00
Two species have wing scales covered in a complex metamaterial
Business
Oxford–AstraZeneca vaccine joins others with promising interim data
2020-11-24T13:09:00
Cheap and fridge-stable candidate at least 60% and up to 90% effective at preventing disease
Business
Regulatory panel unconvinced by Alzheimer’s antibody evidence
2020-11-20T09:29:00
US FDA advisors vote against approving Biogen’s aducanumab on the basis of incomplete data analysis
Business
Moderna and Pfizer’s Covid-19 vaccines add more encouraging data
2020-11-18T14:27:00
Pfizer–BioNTech reach safety threshold for emergency authorisation, while Moderna’s data peek suggests 95% efficacy
Business
Early indications suggest Pfizer–BioNTech’s Covid-19 vaccine is effective
2020-11-10T15:29:00
Company claims 90% efficacy at preventing disease, but experts call for data rather than press releases
News
Millions of microplastic particles released by some baby feeding bottles
2020-10-28T14:30:00
Hot water is key variable responsible for release of large numbers of plastic particles
News
First Covid-19 challenge study working with live virus planned for the UK
2020-10-20T13:52:00
Pending ethics panel approval, healthy volunteers would be infected with Sars-CoV-2 to help understand disease and test vaccines
Business
Protein-based Covid-19 vaccines could overshadow rivals
2020-09-17T13:27:00
Although slower to develop, protein-based vaccines are well understood with a strong record of safety and effectiveness
News
Rush to approve Covid vaccine prompted by politics may end in disaster
2020-09-16T08:30:00
Push by governments to pass a vaccine without appropriate evidence could damage fight against virus
Business
Russian Covid-19 vaccine data raises questions
2020-09-11T09:17:00
Suspected data manipulation or fabrication casts shadows over safety trial report for hastily-approved Sputnik V
Business
Russian vaccine launch shocks scientists
2020-08-14T14:36:00
Sputnik V to be approved without large human trial data
Business
Encouraging signs from initial Covid-19 vaccine trials
2020-08-11T08:28:00
Human trials deliver positive immune responses, while primate challenge studies suggest protection is possible

More by Anthony King